Teclistamab

Overview

JNJ-64007957 is a bispecific antibody that targets BCMA, which is expressed in mature B lymphocytes, and CD3, which is expressed on T-cells.

SparkCures ID 279
Developed By Janssen Research & Development
Generic Name Teclistamab
Additional Names JNJ-64007957
Treatment Classifications
Treatment Targets

Clinical Trials

All Clinical Trials

View all active clinical trials around the US.

Early Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.

Late Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.

Smoldering Myeloma
Monoclonal Gammopathy of Undetermined Significance (MGUS)

Published Results

Teclistamab Appears Safe at All Doses for Relapsed/Refractory Myeloma Treatment

May 30, 2020

  • The study involved 78 patients with relapsed/refractory myeloma who received teclistamab — a bispecific duo antibody that binds to BCMA and CD3 – intravenously.
  • Median age was 64 years old (range, 24-82), and the median number of prior therapies was 6 (range, 2-14).
  • Overall, 72% of participants were triple-class exposed, 62% triple-class refractory, and 51% penta-drug refractory.
  • Part 1 of the study was a dose-escalation trial, with a primary objective of finding the doses for part 2. Doses ranged from 0.3-720 µg/kg weekly, and there was a 67% overall response rate (ORR; 50% ≥ VGPR) at 270 µg/kg.
  • "Response rates increased with higher doses of teclistamab," Dr. Usmani said.

Resources

There are no resources, links or videos to display for this treatment.